By Assoc. Prof. Dr. Mehmet Sorar | Published: 05.02.2025
Deep Brain Stimulation (DBS) in Parkinson’s Disease
Deep brain stimulation (DBS) sends electrical pulses through electrodes in movement-control areas of the brain to help control Parkinson’s symptoms when medicines are not enough. Randomised trials show benefits for movement symptoms and quality of life, together with more serious adverse events than medicine alone. DBS has not been shown to slow the disease. This page sets out who was studied, what was found and what harms were counted.
Who is considered for DBS in Parkinson’s disease?
People whose symptoms are no longer controlled well enough by medicine are considered. The Parkinson’s Foundation lists these features of a typical candidate:
- A specialist has confirmed the diagnosis, and levodopa, the most widely used Parkinson’s medicine, gives at least some benefit.
- “Off” time (periods when medicine is not controlling symptoms) or medicine side effects continue despite adjustments, or tremor does not respond to medicine.
- There are no serious mood, mental-health or cognitive problems.
- You are fit for surgery and have support during recovery.
The Foundation names three possible targets, the globus pallidus internus, the subthalamic nucleus and the ventral intermediate nucleus, and says the choice depends on symptoms and goals. Its page gives no age limit. It says the 2016 approval by the US Food and Drug Administration (FDA) covered earlier-stage disease, with at least four years since diagnosis and movement symptoms not adequately controlled by medicine. The trials below enrolled different kinds of people, so check which group resembles you.
What did the randomised trials show?
Four trials give the main numbers. Each tested stimulation in a different group, against a different comparison and over a different time, so the figures should not be added together or ranked.
| Trial | People | Comparison and length | Main result |
|---|---|---|---|
| Weaver and colleagues, JAMA 2009 | 255 people at Hoehn and Yahr stage 2 or more (a scale of how far Parkinson’s has advanced) off medicine, 25% aged 70 or older | DBS on both sides of the brain, in the subthalamic nucleus (60) or globus pallidus (61), against medical therapy alone (134), 6 months | Time “on” (when medicine is working) without troubling dyskinesia (involuntary jerky movements) rose by 4.6 hours a day with DBS and 0 with medicine (difference 4.5 hours). Meaningful motor improvement in 71% against 32%. |
| Deuschl and colleagues, NEJM 2006 | 156 people under 75 with advanced disease and severe motor complications | Subthalamic stimulation plus medicine against medicine alone, in matched pairs, 6 months | Quality of life better with stimulation in 50 of 78 pairs (mean gain 9.5 points). Off-medicine motor severity better in 55 of 78 pairs (mean gain 19.6 points). |
| EARLYSTIM, NEJM 2013 | 251 people with early motor complications, mean age 52, mean disease duration 7.5 years | Subthalamic stimulation plus medication against medication alone, 2 years | Quality of life improved by 7.8 points with stimulation and worsened by 0.2 with medication alone. Motor disability, daily living and time with good mobility without dyskinesia were also better. |
| INTREPID, JAMA Neurology 2025 | 313 enrolled, 191 implanted, 72% of those completed follow-up, mean age 60 | Trial against a sham (pretend) procedure, then open-label follow-up to 5 years with no comparison group | Off-medication motor score improved 51% at year 1 and 36% at year 5. Total medicine dose, counted as levodopa equivalent, fell 28%. |
Weaver and Deuschl are more than ten years old and followed people for only six months. EARLYSTIM is also more than ten years old, and its participants were relatively young and early in their motor complications, so its results should not be assumed to apply to older or cognitively impaired people. INTREPID was linked to industry and enrolled selected people, with more than 5 years of symptoms, more than 6 hours a day of poor motor function and at least 33% improvement on levodopa. Its results apply to people who respond to levodopa.
What harms did the trials report?
All four trials report harms alongside benefit, and the numbers are not comparable across them:
- Weaver: at least one serious adverse event in 49 DBS patients and 15 medicine patients. Thirty-nine events were related to the surgical procedure, one person died of bleeding in the brain, and tests showed small decrements in some information-processing areas with DBS.
- Deuschl: serious adverse events in 13% with stimulation and 4% with medicine alone, including one fatal bleed in the brain. Overall adverse events were more frequent in the medicine group (64% against 50%), but that difference was not statistically significant.
- EARLYSTIM: serious adverse events in 54.8% with stimulation and 44.1% with medication alone. Serious events related to implantation or the device occurred in 17.7% of the stimulation group.
- INTREPID: infection was the most common serious adverse event (9 participants). Ten deaths were reported, none judged related to the study.
The Parkinson’s Foundation lists risks without percentages: temporary pain, numbness and swelling, infection (mostly of the scalp or chest, with brain infection very rare), allergic reaction to implant materials, temporary confusion especially in older adults, and rare seizures, usually within 24 hours.
Does DBS slow Parkinson’s disease or help every symptom?
It has not been shown to slow the disease, and it does not help every symptom. The 2018 evidence review by the International Parkinson and Movement Disorder Society (MDS) rated subthalamic and pallidal DBS on both sides as clinically useful for motor fluctuations (times when medicine wears off) and dyskinesia, and found no clinically useful intervention to prevent or delay progression.
The Parkinson’s Foundation says DBS may not help mood, energy or walking if these did not respond to levodopa before surgery. It adds that many people take less medicine afterwards, but most continue some. Any reduction is planned by your treating team, so do not cut down on your own. The INTREPID authors say outcomes declined slightly over five years, possibly because of disease progression, but significant benefit persisted. What follow-up looks like is described in life after Parkinson’s surgery.
When should you ask for an assessment, and when is it urgent?
Raise DBS with the neurologist who manages your medicines if off time or medicine side effects persist despite adjustments, or if tremor does not respond to medicine. There is no set deadline for an assessment. The decision follows an examination, and the Foundation says pre-surgery work includes a symptom and cognitive evaluation and an MRI or CT scan. Referral and options are covered in Parkinson’s surgery options and referral, and newer approaches in how strong the evidence is for newer approaches.
If you already have a DBS system, a seizure, sudden weakness, trouble speaking or sudden confusion needs emergency help at once. Call emergency services (112 in Türkiye) and do not wait to reach the implanting team. Phone that team the same day about fever or about redness or discharge at a wound. The full list of warning signs is in life after Parkinson’s surgery. How DBS works across conditions is explained in what deep brain stimulation is and DBS for movement disorders.
Sources
- Parkinson’s Foundation: Deep brain stimulation
- JAMA: Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease, a randomized controlled trial (2009)
- New England Journal of Medicine: A randomized trial of deep-brain stimulation for Parkinson’s disease (2006)
- New England Journal of Medicine: Neurostimulation for Parkinson’s disease with early motor complications, EARLYSTIM (2013)
- JAMA Neurology: Five-year outcomes from deep brain stimulation of the subthalamic nucleus for Parkinson disease, INTREPID (2025)
- Movement Disorders: MDS evidence-based medicine review, treatments for the motor symptoms of Parkinson’s disease (2018)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: Parkinson